|
TREATMENT INFORMATION
Treatments can be complicated. Finding out what your medications are doing for you and learning how to live with the regimens and the side-effects can be equally complicated. We will help you to find what you need and assist you in your search. The library is also available to health care providers and students seeking to learn more about HIV medications.
Treatment Information Library
The Vancouver Island Persons with HIV/AIDS Society (VPWAS) provides a comprehensive, up-to-date HIV treatment Information Library.
Reference material includes: current guidelines for the treatment of HIV/AIDS; plain language fact sheets on HIV medications, side-effects and related conditions, actively recruiting clinical drug trials in Canada, and comprehensive information on nutrition, complementary therapies and other self-care strategies for people with HIV.
Other services include post-test counseling by trained peer (HIV+) supporters, interpretation of lab tests, and general health promotion information.
The Treatment Information Library is available Monday to Friday from 11:00 am to 4:00 pm.
The following is an index to files and information we have available:
Last update: January 2011
1.0 EPIDEMIOLOGY AND TRANSMISSION of HIV
1.1 CLASSIFICATION AND STAGING OF HIV DISEASE
1.2 STUDIES IN MORTALITY/SURVIVAL
1.3 HIV-1: ORIGINS & HISTORY
1.4 STATISTICS
1.4.1 BRITISH COLUMBIA (includes Vancouver Island)
1.4.2 CANADA
1.5 TRANSMISSION of HIV
1.5.1 GENERAL INTRODUCTION (includes safer sex guidelines)
1.5.2 ORAL TRANSMISSION [includes saliva, sex, bites and kissing - see also 1.5.1]
1.5.3 CONTRACEPTIVE DEVICES (CONDOMS) & MICROBICIDES
1.5.5 IS “RE-INFECTION” POSSIBLE? (Why HIV+ people need to practice safer behaviors)
1.5.6 TRANSMISSION OF MULTI-DRUG RESISTANT HIV
1.6 OTHER SEXUALLY TRANSMITTED DISEASES (general overview & how they influence HIV transmission)
1.7 PRE-EXPOSURE PROPHYLAXIS (with Truvada)
2.0 HIV AND THE IMMUNE SYSTEM
2.1 GENERAL INTRODUCTION TO THE IMMUNE SYSTEM & HOW HIV CAUSES AIDS
2.2. THE SCIENTIFIC REFUTATION OF (PETER DUESBERG’S & OTHER) NON-HIV THEORIES OF AIDS
2.4 STRUCTURED TREATMENT HOLIDAYS – is it safe?
2.5 THE QUEST FOR A CURE
2.6 WHY SOME PEOPLE ARE RESISTANT TO HIV INFECTION AND/OR DISEASE PROGRESSION
3.0 LABORATORY TESTS
3.1 INTERPRETING BASIC LAB TESTS
3.2 THE HIV ANTIBODY TEST (includes reason for persistently sero-negative persons infected with HIV)
3.3 SURROGATE MARKERS OF DISEASE PROGRESSION (CD4, CD8, etc. and their interpretation)
3.4 VIRAL LOAD TESTS AND DISEASE PROGRESSION
3.4.1 SIMPLE FACT SHEETS (includes interpretation of tests)
3.4.2 VIRAL LOAD (prognosis, “blips”, and durability of treatment)
4.0 TREATMENT FOR HIV INFECTION
4.1 General overview of HIV drugs/ and treatment decision-making
4.3 ANTIRETROVIRAL THERAPY
4.3.1 ACUTE PRIMARY INFECTION: symptoms and rationale for early treatment
4.3.2 TREATMENT STRATEGIES for chronic HIV infection
4.3.2.1 CURRENT RECOMMENDATIONS (when to start & what to start with)
4.3.2.2 DRUG RESISTENCE & OTHER REASONS FOR DRUG FAILURE
4.3.3 REVERSE TRANSCRIPTASE INHIBITORS (nucleoside/nucleotide analogs)
4.3.3.1 COMBIVIR (co-formulated AZT+3TC)
4.3.3.3 abacavir/ Ziagen (includes hypersensitivity test)
4.3.3.4 KIVEXA (co-formulated 3TC+abacavir)
4.3.3.5 tenofovir/ Viread
4.3.3.6. TRUVADA (co-formulated tenofovir+FTC)
4.3.3.8 ATRIPLA (co-formulated Truvada + Sustiva) (see also 4.3.3.6) 4.3.4 REVERSE TRANSCRIPTASE INHIBITORS (non-nucleoside analogs)
4.3.4.1 neviripine/Viramune (includes XR formulation)
4.3.4.2 efavirenz/Sustiva
4.3.4.3 etravirine/Intelence
4.3.4.4 rilpivirine (TMC-278) – Phase II/III studies
4.3.5 PROTEASE INHIBITORS
4.3.5.2 ritonavir/Norvir
4.3.5.4 atazanavir/Rayataz (includes comparison with Kaletra)
4.3.5.6 lopinavir+ritonavir/ Kaletra
4.3.5.7 darunavir/ Prezista
4.3.6 INTEGRASE INHIBITORS
4.3.6.1 raltegravir/ Isentress
4.3.6.2 elvitegravir (GS-9137) – Phase II/III studies (includes “quad” pill)
4.3.6.3 GSK-572 (phase II/III studies)
0.0.1 FUSION, ENTRY, ATTACHMENT & MATURATION INHIBITORS
0.0.1.1 maraviroc/Celsentri (Selzentry in the US) (CCR5 antagonist)/includes tropism assay
0.0.1.2 entry/fusion inhibitors : general intro & drugs in development
4.5 METABOLIC & OTHER COMPLICATIONS WITH HIV AND/OR HAART
4.5.1 GENERAL OVERVIEW OF SIDE-EFFECT & TOXICITY MANAGEMENT
4.5.2 METABOLIC SYNDROME/LIPODYSTROPHY
4.5.2.1 OVERVIEW & DEFINITIONS (see also 4.3.2.4)
4.5.2.2 Experimental treatments (statins, glitizones, etc.)
4.5.2.3 Experimental treatments: leptin
4.5.2.4 Experimental treatments: HGH: Serostim
4.5.2.5 Experimental treatments: HGH: tesamorelin/Egrifta
4.5.3 RISK of CARDIAC & STROKE PROBLEMS
4.5.3.1 OVERVIEW
4.5.3.2 LIFESTYLE MANAGEMENT (diet, exercise, supplements)
4.5.3.3 STATINS & FIBRATES
4.5.4 DIABETES, INSULIN RESISTANCE & HAART
4.5.5 BONE PROBLEMS & HAART
4.5.6 IMMUNE RECONSTITUTION & HAART
4.5.7 KIDNEY PROBLEMS & HAART
4.5.8 LIVER PROBLEMS & HAART
4.5.9 SEXUAL DYSFUNCTION & HAART
4.5.10 FACIAL WASTING & POSSIBLE TREATMENTS
4.5.13 THYROID PROBLEMS & HAART
4.5.14 HYPERTENSION & HAART
4.5.15 GOUT & HAART
4.5.16 ARTHRITIS & HARRT
4.6 OTHER EXPERIMENTAL APPROACHES
4.6.1 THERAPEUTIC VACCINES & IMMUNE THERAPIES
4.6.2 GENE THERAPIES
0.1 AGEING, INFLAMMATION & HIV
1.0 OTHER PROBLEMS ASSOCIATED WITH HIV
0.01 LUNG PROBLEMS
0.02 SKIN PROBLEMS
0.03 BLOOD ABNORMALITIES
0.04 NEURO-PSYCHIATRIC PROBLEMS
5.4.1 GENERAL OVERVIEW
5.4.2 DEMENTIA & AGEING (cognitive/motor dysfunction)
5.4.3 DEPRESSION & MOOD DISORDERS
5.4.4 PML (progressive multifocal leukoencephalopathy)
5.5 ORAL / DENTAL PROBLEMS (for oral & throat cancers see 7.3.1)
5.6 FATIGUE & HIV
5.7 NEUROPATHY
5.8 PAIN MANAGEMENT IN HIV
5.9 GASTRO-INTESTINAL PROBLEMS (includes coping with nausea & diarrhea)
5.10 WASTING DISORDER (severe unintentional weight loss)
5.11 HYPOGONADISM (testosterone replacement therapy)
6.0 OPPORTUNISTIC INFECTIONS ASSOCIATED WITH HIV/AIDS
6.01 OPPORTUNISTIC INFECTIONS - BASIC INTRODUCTION AND OVERVIEW
6.1 MYCOBACTERIAL INFECTIONS (MAC & TB)
6.2 FUNGAL INFECTIONS
6.2.1 CANDIDA
6.2.2 CRYPTOCOCCOSIS (includes meningitis)
6.2.3 PNEUMOCYSTIS PNEUMONIA
6.3 VIRAL INFECTIONS AND TREATMENTS
6.3.1 HERPES SIMPLEX
6.3.2 HERPES ZOSTER (includes shingles vaccine info)
6.3.3 Valacyclovir & Famcyclovir: treatment for herpes
6.3.4 CYTOMEGALOVIRUS
6.4 PROTOZOAN INFECTIONS AND TREATMENTS
6.4.1 CRYPTOSPORIDIOSIS
6.4.2 TOXOPLASMOSIS
6.5 BACTERIAL INFECTIONS (includes staph/MRSA)
7.0 MALIGNANCIES (CANCERS) ASSOCIATED WITH HIV/AIDS
7.01 EPIDEMIOLOGY OF CANCERS in HIV (overview)
7.1 KAPOSI'S SARCOMA
7.1.1 SYMPTOMS AND TREATMENTS
7.1.2 KS is associated with sexually transmitted Human Herpes Virus 8
7.2 LYMPHOMA
7.3 HUMAN PAPILLOMA VIRUS
7.3.1 GENERAL OVERVIEW
7.3.2 HPV & ANAL-GENITAL CANCERS
7.3.3 HPV VACCINES
7.3.4 HPV & ORAL CANCERS
7.4 HIV & COLO-RECTAL CANCER
7.5 HIV & PROSTATE CANCER
7.6 HIV & LUNG CANCER (see also 10.2)
NUTRITION IN HIV
9.1.1 GENERAL INTRO TO HIV NUTRITION
9.1.2 DETAILED STUDIES
9.1.3 PRECAUTIONS WITH VITAMINS
9.2 LIQUID NUTRITIONAL SUPPLEMENTS
9.3 GLUTAMINE
9.4 N-acetyl cysteine & GLUTATHIONE
9.5 VITAMIN D & HIV
10.0 SELF-CARE STRATEGIES FOR THE HIV+PERSON
10.1 ALCOHOL AND OTHER RECREATIONAL DRUGS AND HIV
10.2 TOBACCO SMOKING AND HIV (see also 7.6)
10.3 VACCINATIONS FOR THE HIV+ PERSON
10.4 HIV & TRAVEL: PRE-TRAVEL RECOMMENDATIONS AND HEALTH RISKS
Medical Disclaimer
Decisions about particular medical treatments should always be made in consultation with a qualified medical practitioner knowledgeable about HIV-related illness and treatment.
The Vancouver Island Persons Living with HIV/AIDS Society (VIPWAS) does not recommend or advocate particular treatments and we urge users to consult as broad a range of sources as possible.
|
